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Background: Atrial ﬁbrillation (AF) is the most common supraventricular tachyarrhythmia in patients
with acute myocardial infarction (AMI). However, little is known about the impact of AF on in-hospital
and long-term mortalities in patients with AMI in the era of primary percutaneous coronary
intervention (PCI).
Methods: Six hundred ninety-four consecutive patients with AMI admitted within 48 h after symptom
onset were analyzed. All patients successfully underwent primary PCI at the acute phase of AMI. Patients
were divided into 2 groups according to the presence of AF at admission or during index hospitalization.
We retrospectively evaluated the in-hospital and long-term all-cause mortalities between patients with
and those without AF.
Results: AF was detected in 38 patients (5.5%) at admission and in 51 patients (7.3%) during hospitaliza-
tion. Patients with AF were older and had a higher heart rate, lower ejection fraction, higher prevalence
of hypertension, worse renal function, higher peak level of creatine phosphokinase, and lower rate of
ﬁnal TIMI ﬂow grade 3 than those without AF. Although patients with AF had a more complicated clinical
course and higher in-hospital mortality (11.2% vs. 4.0%, P¼0.009), there was no signiﬁcant association
between presenting AF and in-hospital death after adjustment for baseline confounders (odds ratio, 2.63;
95% conﬁdence interval [CI], 0.91–5.47; P¼0.076). During the follow-up period of 3.071.7 years, patients
with AF had a higher all-cause mortality than those without AF (30.3% vs. 22.1%, P¼0.004 by log-rank
test). However, after adjustment for clinical characteristics, presenting AF was not an independent
predictor of all-cause mortality (hazard ratio, 1.15; 95% CI, 0.67–1.88; P¼0.588).
Conclusions: AF is a common complication of AMI and associated with a more complicated clinical
course. However, AF is not an independent predictor of both in-hospital and long-term mortalities in the
PCI era.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Atrial ﬁbrillation (AF) is the most common supraventricular
tachyarrhythmia seen in patients with acute myocardial infarction
(AMI). It has been reported that AF occurs in 5–23% of patients
with AMI [1–4]. AF is triggered by many different conditions,
including left ventricular dysfunction with hemodynamic impair-
ment [5,6], atrial ischemia or infarction [7], pericarditis, chronic
lung disease, acute hypoxia, or electrolyte abnormalities [8,9]. AF
occurring during the acute phase of AMI may adversely affect the
left ventricular function and exacerbate ongoing myocardial
ischemia. The bidirectional interaction between AF and myocardial
dysfunction or ischemia may lead to a vicious circle in a patient
with AF complicating AMI. Some studies have shown an associa-
tion between increased in-hospital and long-term mortalities
and AF [1,10–13], although others have found no independent
effect [2,3,14–17]. Most studies on AF complicated with AMI were
performed in the prethrombolytic or thrombolytic era. Current
treatments for AMI include not only aspirin, β-blockers, and
thrombolytic therapy, but also angiotensin-converting enzyme
inhibitors (ACE-I), angiotensin II receptor blockers (ARB), statin,
and percutaneous coronary intervention (PCI) [18]. PCI has been
shown to be a more effective treatment strategy in patients with
AMI than thrombolytic therapy [19,20], and use of primary PCI
has dramatically increased [21]. However, little is known about the
in-hospital and long-term mortalities in patients with AMI and AF
in the PCI era. We examined the impact of AF on in-hospital and
long-term mortalities in patients with AMI.
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2. Methods
2.1. Study patients
The study protocol was approved by the ethical committee on
human research of our institution. Six hundred ninety-four consecu-
tive AMI patients whowere transferred to Hirosaki University Hospital
within 48 h after symptom onset and underwent primary PCI at the
acute phase of AMI from February 2006 to April 2010 were enrolled.
The diagnosis of AMI was made in the presence of chest pain lasting
Z20min and/or electrocardiographic (ECG) changes suggestive of
myocardial infarction (MI) or ischemia (Z0.1 mV ST-segment eleva-
tion or depression in Z2 contiguous leads and/or appearance of a
new Q-wave), accompanied by an increase of creatine phosphokinase
myocardial isoform (CPK-MB) and/or a cardiac troponin T-value
greater than the upper reference limit. AF was deﬁned electrocardio-
graphically as the absence of P-waves, coarse or ﬁne ﬁbrillation waves,
and completely irregular R-R interval, and was diagnosed by 12-lead
ECG or ECG monitoring by at least 2 cardiologists.
The study population was divided into 2 groups: patients who
had AF at admission or developed AF during hospitalization (any-
AF group) and those without AF (non-AF group). The any-AF group
was further divided into 2 subgroups: patients who had AF at
admission (AF at admission) and those who did not have AF at
admission but developed AF during the index hospitalization (AF
during hospitalization). Patients with a history of paroxysmal or
transient AF but without a recurrence of AF during the index
hospitalization were categorized into the non-AF group.
2.2. Primary PCI
Primary PCI was performed in accordance with the ACC/AHA/
SCAI Practice Guidelines for Percutaneous Coronary Intervention
[22]. Patients admitted within 12 h of symptom onset were
indicated for primary PCI. Those admitted within 36 h of AMI
onset and complicated with cardiogenic shock, or those admitted
after 12 h but within 24 h and complicated with severe heart
failure, hemodynamic or electrical instability, or evidence of
persistent ischemia also underwent primary PCI. Patients who
were admitted 412 h after AMI onset and were hemodynamically
and electrically stable were not submitted to primary PCI. A bare
metal stent was used for PCI when stenting was indicated.
2.3. Endpoints
The primary endpoint of the study was all-cause death. We
retrospectively evaluated the in-hospital and long-term all-cause
mortalities. We also examined the association of AF with in-hospital
events, including congestive heart failure (CHF), cardiogenic shock,
ventricular tachycardia/ﬁbrillation (VT/VF), stroke, and length of
hospitalization. Follow-up started from the day of admission. The
patients were followed for 3.071.7 years. After hospital discharge,
follow-up data were obtained from the following 3 ways: reviewing
patients' hospital records, interviewing the patients through tele-
phone, and examining the patients in outpatient clinics.
2.4. Statistical analysis
Continuous parameters were expressed as mean7SD, and
categorical variables as number and percentage. Comparative
analysis among groups was performed with Student's t test or
ANOVA for continuous variables and chi-square test for categorical
variables. For comparison of non-AF, AF at admission, and AF
during hospitalization, Tukey's honest signiﬁcant difference test
multiple-comparison procedure was used to identify where the
differences among the 3 groups occurred after the signiﬁcant
ANOVA. A multivariate logistic regression model was used to
analyze factors that inﬂuenced the prevalence of AF. The following
variables were entered into the model: age 465 years, male sex,
heart rate at admission 4100/min, left ventricular ejection frac-
tion (LVEF) o40%, anterior MI, peak level of CPK 43000 IU/L, ﬁnal
TIMI ﬂow grade 3, and Killip class at admission 4 I. The prognostic
impact of AF on in-hospital mortality was examined using a
multivariate logistic regression model, adjusting for age 465
years, LVEF o40%, and ﬁnal TIMI ﬂow grade 3. Kaplan–Meier
curves for long-term all-cause mortality among the groups were
constructed and compared using the log-rank test. Univariate and
multivariate Cox proportional hazard analyses were performed to
identify hazard ratios (HR) and 95% conﬁdence intervals (CI). All
AF categories (any-AF, AF at admission, and AF during hospitaliza-
tion) were tested in a univariate model and furthermore in a
multivariate model adjusted for clinical prognostic factors, includ-
ing age 465 years, male sex, LVEF o40%, estimated glomerular
ﬁltration rate (eGFR) o60 mL min1 1.73 m2, anterior MI, peak
level of CPK 43000 IU/L, heart rate at admission 4100/min, and
ﬁnal TIMI ﬂow grade 3. All statistical analyses were done using
JMP 10.0.2 (SAS Institute Inc., Cary, NC, USA). A P value of o0.05
was considered signiﬁcant.
3. Results
3.1. Baseline characteristics and relation to AF
The baseline characteristics of the patients are summarized in
Table 1. Of the 694 patients, AF was diagnosed in 89 (12.8%, any-AF
group) at admission (38 patients, 5.5%) or during hospitalization (51
patients, 7.3%). Of the 89 patients with AF, AF was terminated
spontaneously in 31 (34.8%), by electrical cardioversion in 17 (19.1%),
with intravenous or oral administration of amiodarone in 29 (32.6%),
with intravenous β-blocker in 7 (10.8%), and was not terminated
during index hospitalization in 23 (25.8%). Patients with any-AF were
older and had a higher heart rate, lower LVEF, lower eGFR, higher
prevalence of hypertension, higher peak level of CPK, lower rate of
ﬁnal TIMI ﬂow grade 3, and higher prevalence of previous AF than
those without AF. Particularly, patients with AF at admission had a
signiﬁcantly higher heart rate at admission and a higher prevalence of
previous AF. Patients with AF during hospitalization had a higher
prevalence of hypertension than those without AF. No signiﬁcant
difference was found in sex, body mass index, left atrial dimension,
diabetes mellitus, anterior MI, time from symptom onset to presenta-
tion, Killip class at admission, history of MI, stroke, and previous PCI.
Multivariate logistic regression analysis revealed that age 465 years,
male sex, heart rate 4100/min, and peak level of CPK 43000 IU/L
were independent predictive factors of the prevalence of AF (Table 2).
The medication at discharge is shown in Table 3. Patients with AF
were more commonly treated with warfarin and β-blockers, but were
less administered thienopyridine. There were no signiﬁcant difference
in the treatments with ACE-I, ARB, and statin between the non-AF and
any-AF groups. Eighty-four patients (12.7%) were treated with aspirin,
thienopyridine, and warfarin (triple antithrombotic therapy). Triple
antithrombotic therapy was more frequently administered in patients
with AF than in those without AF. Neither use of warfarin nor use of
antiplatelet drugs had a signiﬁcant relation to long-term mortality.
3.2. Impact of AF on in-hospital events
CHF, cardiogenic shock, and VT/VF occurred more often in
patients in the any-AF group than in those in the non-AF group,
and hospitalization was also longer in patients with than in those
without AF. There was no signiﬁcant difference in the incidence of
in-hospital stroke (Table 4). Of the 34 patients (4.9%) who died
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during index hospitalization, most deaths (91.2%) were of cardio-
vascular causes. The unadjusted in-hospital mortality was signiﬁ-
cantly higher in the any-AF group than in the non-AF group (11.2%
vs. 4.0%, P¼0.009) (Table 4). However, there was no signiﬁcant
Table 2
Predictors of atrial ﬁbrillation.
OR 95% CI P value
Age 465 years 3.26 1.94–5.66 o0.001
Male 1.90 1.05–3.60 0.033
Heart rate at admission 4100/min 6.42 1.86–6.20 o0.001
LVEF o40% 1.08 0.62–1.84 0.788
Anterior MI 1.43 0.86–2.39 0.171
Peak CPK 43000 IU/L 1.81 1.08–3.03 0.023
Final TIMI ﬂow grade 3 0.74 0.42–1.34 0.321
Killip class at admission 41 1.61 0.92–2.74 0.094
OR, odds ratio; 95% CI, 95% conﬁdence interval; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; and CPK, creatine phosphokinase.
Table 1
Baseline characteristics at presentation.
All (n¼694) Non-AF
(n¼605, 87.2%)
Any-AF
(n¼89, 12.8%)
AF at admission
(n¼38, 5.5%)
AF during hospitalization
(n¼51, 7.3%)
P valuea
Age (years) 66712 65713 7279 72710b 7278b o0.001
Male, n (%) 525 (75.6) 454 (75.0) 71 (79.8) 30 (79.0) 41 (80.4) 0.323
Median follow-up (days) 10957626 11137620 9787657 8347627b 10847664 0.058
Body mass index (kg/m2) 24.173.6 24.273.6 23.773.5 23.373.9 24.073.2 0.228
Heart rate at admission (/min) 78720 78719 84728 91731b 79723 0.003
LVEF (%) 46.2710.3 46.979.8 41.9712.3 41.8713.7b 42.0711.2b o0.001
Left atrial dimension (mm) 36.075.7 35.975.8 36.575.5 34.872.5 37.176.2 0.616
Diabetes mellitus, n (%) 267 (38.5) 227 (37.5) 40 (44.9) 16 (42.1) 24 (47.1) 0.182
Hypertension, n (%) 465 (67.0) 397 (65.6) 68 (76.4) 26 (68.4) 42 (82.4) b 0.038
eGFR (mL min1 1.73 m2) 59.3722.7 60.3722.2 52.8724.8 52.2721.6b 53.3727.1b 0.004
Anterior MI, n (%) 337 (48.6) 297 (49.1) 40 (44.9) 15 (39.5) 25 (49.0) 0.464
Peak CPK (IU/L) 323873053 299572689 488674541 451775121b 516074087b o0.001
Final TIMI ﬂow grade 3, n (%) 560 (80.7) 496 (82.0) 64 (71.9) 27 (71.1) 37 (72.6) 0.031
Time from symptom onset to presentation, n (%)
≦6 h 455 (65.6) 396 (65.5) 59 (66.3) 27 (71.1) 32 (62.8) 0.091
6–12 h 126 (18.2) 108 (17.9) 18 (20.2) 8 (21.1) 10 (19.6)
12–24 h 82 (11.8) 77 (12.7) 5 (5.6) 0 (0.0) 5 (9.8)
24–48 h 31 (4.5) 24 (4.0) 7 (7.9) 3 (7.9) 4 (7.8)
Killip class at admission, n(%)
I 557 (80.3) 493 (81.5) 64 (71.9) 30 (79.0) 34 (66.7) 0.236
II 52 (7.5) 42 (6.9) 10 (11.2) 2 (5.3) 8 (15.7)
III 47 (6.8) 39 (6.5) 8 (9.0) 2 (5.3) 6 (11.8)
IV 38 (5.5) 31 (5.1) 7 (7.9) 4 (10.5) 3 (5.9)
History of, n (%)
AF 16 (2.3) 3 (0.5) 13 (14.6) 11 (29.0)b 2 (3.9) o0.001
MI 40 (5.8) 37 (6.1) 3 (3.4) 1 (2.6) 2 (3.9) 0.267
Stroke 44 (6.3) 42 (6.9) 2 (2.3) 0 (0.0) 2 (3.9) 0.056
PCI 32 (4.6) 29 (4.8) 3 (3.4) 1 (2.6) 2 (3.9) 0.534
AF, atrial ﬁbrillation; LVEF, left ventricular ejection fraction; eGFR, estimate glomerular ﬁltration rate; MI, myocardial infarction; CPK, creatine phosphokinase; and PCI,
percutaneous coronary intervention.
a Any-AF vs. non-AF.
b Po0.05 vs. non-AF.
Table 3
Baseline treatment at discharge.
All
(n¼660)
Non-AF
(n¼581, 88.0%)
Any-AF
(n¼79, 12.0%)
P value
Aspirin, n (%) 653 (98.9) 575 (99.0) 78 (98.7) 0.853
Thienopyridine, n (%) 622 (94.2) 555 (97.5) 67 (84.8) o0.001
ACE-I or ARB, n (%) 606 (91.8) 532 (91.6) 74 (93.7) 0.508
β-Blocker, n (%) 562 (85.2) 488 (84.0) 74 (93.7) 0.013
Statin, n (%) 531 (80.5) 471 (81.1) 60 (76.0) 0.293
Warfarin, n (%) 97 (14.7) 52 (9.0) 45 (57.0) o0.001
Triple antithrombotic
therapy, n (%)
84 (12.7) 46 (7.9) 38 (48.1) o0.001
AF, atrial ﬁbrillation; ACE-I, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker; and Triple antithrombotic therapy, aspirin, thieno-
pyridine, and warfarin.
Table 4
In-hospital events.
All (n¼694) Non-AF
(n¼605, 87.2%)
Any-AF
(n¼89, 12.8%)
P value
In-hospital death,
n (%)
34 (4.9) 24 (4.0) 10 (11.2) 0.009
CHF, n (%) 136 (19.6) 105 (17.4) 31 (34.8) o0.001
Cardiogenic shock,
n (%)
39 (5.6) 28 (4.6) 11 (12.4) 0.008
VT/VF, n (%) 31 (4.5) 22 (3.6) 9 (10.1) 0.014
Stroke, n (%) 12 (1.7) 9 (1.5) 3 (3.4) 0.250
Hospitalization,
days
1779 1777 20715 o0.001
AF, atrial ﬁbrillation; CHF, congestive heart failure; VT, ventricular tachycardia; and
VF, ventricular ﬁbrillation.
Table 5
Multivariate analysis (in-hospital death).
OR 95% CI P value
Any-AF 2.31 0.91–5.47 0.076
Age 465 years 1.85 0.80–4.66 0.156
LVEF o40 % 4.55 2.02–10.91 o0.001
Final TIMI ﬂow grade 3 0.34 0.15–0.78 0.011
OR, odds ratio; 95% CI, 95% conﬁdence interval; AF, atrial ﬁbrillation; and LVEF, left
ventricular ejection fraction.
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association between AF and in-hospital mortality (odds ratio [OR],
2.31; 95% CI, 0.91–5.47; P¼0.076) after adjustment for baseline
confounders (Table 5). Furthermore, when stratiﬁed by AF sub-
groups, neither AF at admission nor AF during hospitalization was
an independent predictor of in-hospital mortality.
3.3. Impact of AF on long-term mortality
During a follow-up period of 3.071.7 years, a total of 114 patients
(16.4%) died. Most deaths (47.4%) were of cardiovascular causes. The
Kaplan–Meier survival curves showed that the unadjusted long-term
mortality was signiﬁcantly higher in the any-AF group than in the
non-AF group (Fig. 1). When comparing the AF subgroups with the
non-AF group, both the AF at admission and AF during hospitaliza-
tion groups had a higher mortality than the non-AF group (Fig. 1).
There was no signiﬁcant difference in long-term mortality between
the 2 any-AF subgroups (Fig. 1).
In the univariate Cox proportional hazard model, the hazard
ratios (95% CI) of any-AF, AF at admission (vs. non-AF), and AF at
hospitalization (vs. non-AF) were 1.93 (1.19–3.00), 1.96 (0.92–3.69),
and 1.91 (1.04–3.24), respectively (Table 6). The multivariate analy-
sis by the Cox proportional hazard model revealed that age 465
years (HR, 3.20; 95% CI, 1.97–5.41; Po0.001), LVEF o40% (HR, 1.76;
95% CI, 1.14–2.72; P¼0.012), eGFR o60 mL min1 1.73 m2 (HR,
3.76; 95% CI, 2.32–6.41; Po0.001), heart rate at admission 4100/
min (HR, 1.85; 95% CI, 1.10–2.99; P¼0.021), and ﬁnal TIMI ﬂow
grade 3 (HR, 0.62; 95% CI, 0.39–0.99; P¼0.046) were independent
predictors of long-term mortality. However, presenting AF (HR, 1.15;
95% CI, 0.67–1.88; P¼0.588) was not signiﬁcantly associated with
long-termmortality (Table 7). Furthermore, when comparing the AF
subgroups with the non-AF group, neither AF at admission (HR,
1.05; 95% CI, 0.45–2.13; P¼0.901) nor AF during hospitalization (HR,
1.22; 95% CI, 0.64–2.17; P¼0.530) was an independent predictor of
long-term mortality (Table 6). When limited to 1-year mortality,
patients with AF had a higher mortality rate (18.1% vs. 7.8%,
P¼0.001 by log-rank test), and presenting AF was an independent
predictor (HR, 1.91; 95% CI, 1.03–3.36; P¼0.040) for 1-year mortality
even after adjustment for age 465 years, male sex, anterior MI,
previous MI, and ﬁnal TIMI ﬂow grade 3.
4. Discussion
In patients with AMI in the present study, presenting AF was
associated with higher in-hospital events, including all-cause
death, CHF, cardiogenic shock, and ventricular arrhythmias.
Furthermore, patients with AF had a higher long-term mortality
than those without AF. However, multivariate analysis revealed
that presenting AF was not an independent predictor of both
Fig. 1. Kaplan–Meier curves for unadjusted long-term mortality. (A) Kaplan–Meier
curves for unadjusted long-term mortalities of patients with atrial ﬁbrillation (any-
AF) and those without atrial ﬁbrillation (non-AF). (B) Kaplan–Meier curves for
unadjusted long-term mortalities of patients with atrial ﬁbrillation at admission
(AF at admission), those who developed atrial ﬁbrillation during hospitalization (AF
during hospitalization), and those without atrial ﬁbrillation (non-AF).
Table 6
Hazard ratio of atrial ﬁbrillation for long-term mortality.
Unadjusted HR 95% CI P value Adjusted HRa 95% CI P value
Any-AF 1.93 1.19–3.00 0.009 1.15 0.67–1.88 0.588
AF at admission 1.96 0.92–3.69 0.078 1.05 0.45–2.13 0.901
AF during hospitalization 1.91 1.04–3.24 0.038 1.22 0.64–2.17 0.530
HR, hazard ratio; 95% CI, 95% conﬁdence interval; and AF, atrial ﬁbrillation.
a Adjusted for age 465 years, male sex, LVEF o40%, eGFR o60 mL min1 1.73 m2, anterior MI, peak CPK 43000 IU/L, heart rate at admission 4100/min, and ﬁnal
TIMI ﬂow grade 3.
Table 7
Cox proportional hazards model for long-term mortality.
HR 95% CI P value
Any-AF 1.15 0.67–1.88 0.588
Age 465 years 3.20 1.97–5.41 o0.001
Male 0.62 0.37–1.01 0.055
LVEF o40% 1.76 1.14–2.72 0.012
eGFR o60 mL min1 1.73 m2 3.76 2.32–6.41 o0.001
Anterior MI 1.18 0.48–1.80 0.437
Peak CPK 43000 IU/L 1.02 0.66–1.56 0.934
Heart rate at admission 4100/min 1.85 1.10–2.99 0.021
Final TIMI ﬂow grade 3 0.62 0.39–0.99 0.046
HR, hazard ratio; 95% CI, 95% conﬁdence interval; AF, atrial ﬁbrillation; LVEF, left
ventricular ejection fraction; eGFR, estimate glomerular ﬁltration rate; MI, myo-
cardial infarction; and CPK, creatine phosphokinase.
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in-hospital and long-term mortalities. When comparing the AF
subgroups to the non-AF group, neither AF at admission nor AF
during hospitalization was an independent predictor of long-term
mortality. To the best of our knowledge, this is the ﬁrst long-term
follow-up report evaluating the prognostic impact of AF in patients
with AMI in the PCI era. These ﬁndings indicate the importance of
presenting AF during the acute phase of MI even in the PCI era.
4.1. Prevalence of AF in AMI
AF is one of the most common supraventricular arrhythmias in
the setting of AMI. In the present study, AF was a common
complication of AMI, with a prevalence of 12.8%. This prevalence
is slightly higher than has been observed in previous published
studies (7–10%) [3,4,12]. In the GUSTO I trial [3], which included
patients with AMI eligible for thrombolysis, an AF incidence of
10.4% was reported. Wong et al. [4] presented data from the
GUSTO III study and reported a 7.0% incidence of AF. Eldar et al.
[12] reported a 9.8% incidence of paroxysmal AF in patients with
AMI. These were randomized controlled studies, and therefore
high-risk patients were excluded. Moreover, these studies
included only AMI patients with new-onset AF or paroxysmal AF.
Our study included not only AMI patients with new-onset,
transient, and paroxysmal AF but also those with persistent and
permanent AF.
Old age has been reported to be the most important indepen-
dent predictor of AF [3,11,23,24]. In the GUSTO I trial, baseline
clinical characteristics, including age, heart rate, and Killip class at
admission, were found to be signiﬁcant independent predictors of
new AF [3]. We found that patients with AF had worse baseline
clinical characteristics, including advanced age, higher heart rate,
lower LVEF, lower eGFR, higher peak level of CPK, and lower rate of
ﬁnal TIMI ﬂow grade 3 than those without AF. The present study
also showed that in addition to male sex, higher heart rate at
admission, higher peak level of CPK, and previous AF, advanced
age was independently associated with the incidence of AF.
A retrospective analysis of a registry database that included
106,780 Medicare patients 465 years old with AMI showed that
the incidence of AF was 22.1% [2]. This high incidence of AF in
older patients with AMI is consistent with the generally higher
prevalence of AF in elderly persons documented by several
epidemiological studies [25].
4.2. In-hospital events
Consistent with previous reports [3,12,26], our current study
showed that patients with AF had considerably more serious in-
hospital complications than those without AF. The incidences of
CHF, cardiogenic shock, and VT/VF were more frequently observed
in patients with AF than in those without AF. In the GUSTO trial,
patients with AF had a larger infarction size, more extensive
coronary artery disease, poorer reperfusion, and lower LVEF than
those without AF. Similarly, our study showed that patients with
AF had worse baseline clinical characteristics, including advanced
age, higher heart rate, lower LVEF, lower eGFR, higher peak level of
CPK, and lower rate of ﬁnal TIMI ﬂow grade 3 than those without
AF. Although we could not ascertain the precise etiology of AF, the
observation that an increased heart rate and a lower LVEF were
associated with AF suggests that hemodynamic compromise is the
most likely mechanism.
In this study, in-hospital mortality was signiﬁcantly higher in
patients with AF than in those without AF. An adverse impact of AF
on in-hospital mortality in patients with AMI has been reported by
several clinical studies [4,14,26]. In these studies, AF was inde-
pendently associated with in-hospital mortality even after
adjustment for multiple confounders [4,14,26]. On the other hand,
in some reports, the association of AF with mortality appeared to
be related to CHF, cardiogenic shock, and ventricular arrhythmias,
rather than AF itself [11–13,24]. In a recent analysis of AMI patients
treated with PCI [13], Kinjo et al. showed that in-hospital fatal
events occurred more frequently in patients with AF, although
after adjustment for possible confounders, including age, sex, DM,
hypertension, prior MI, prior cerebrovascular disease, systolic
blood pressure o100 mm Hg, heart rate 4100/min, Killip class
IV, left anterior descending artery disease, multivessel disease, and
ﬁnal TIMI ﬂow grade 3, AF was not independently associated with
in-hospital mortality [13]. In our study, patients with AF had a
higher in-hospital mortality in univariate analysis, but presenting
AF was not an independent predictor (OR, 2.31; 95% CI, 0.91–5.47;
P¼0.076) of in-hospital mortality after adjustment for age 465
years, LVEF o40%, and ﬁnal TIMI ﬂow grade 3. This result is
consistent with the report of Kinjo et al. [13].
4.3. Long-term mortality
Previous studies on the impact of AF on mortality in patients
with AMI reported discrepant results, with some studies reporting
no adverse effect on long-term mortality [1,10] and others
reporting an increased risk of death with AF [2,3,11–17]. The
present study demonstrates that AF with AMI was associated with
long-term mortality but was not an independent predictor after
adjustment for relevant predictors. Although the Kaplan–Meier
curves clearly showed increased mortality in patients with AF
regardless of the timing of AF, in multivariate analysis, either AF at
admission or AF during hospitalization was not detected as an
independent predictor of long-term mortality. In a previous study,
patients with AF had a more complicated in-hospital clinical
course; however, AF was not an independent risk factor in in-
hospital and long-term mortalities after adjustment for baseline
characteristics (HR, 1.26; 95% CI, 0.82–1.95; P¼0.283) [10]. Gold-
berg et al. [1] also reported that patients discharged after devel-
oping AF had higher long-term death rates than those who did not
develop AF, although these differences were attenuated after
adjusting for other factors. Taken together, AF was associated with
a more complicated clinical course, such as CHF or cardiogenic
shock and VT/VF, although there was no signiﬁcant association
between presenting AF and worse long-term mortality after
adjustment for relevant predictors. The presence of AF reﬂects
the overall poor clinical status, and, consequently, might reﬂect
the worse prognosis in previous studies. Kinjo et al. showed that
patients with AF had signiﬁcantly greater risk for mortality at
1 year even after adjustment for demographic characteristics and
clinical factors [13]. Differences in the inclusion criteria, data
adjustment, and follow-up period can at least partially account
for the discrepant results between this study and the previous
studies. In our study, when limited to 1-year mortality, patients
with AF had a higher mortality rate (18.1% vs. 7.8%, P¼0.001 by
log-rank test), and presenting AF was an independent predictor
(HR, 1.91; 95% CI, 1.03–3.36; P¼0.040) of 1-year mortality even
after adjustment for age 465 years, male sex, anterior MI,
previous MI, and ﬁnal TIMI ﬂow grade 3. This result is consistent
with the report of Kinjo et al. [13].
Although no signiﬁcant statistical associationwas found, AF tended
to be associated with higher in-hospital mortality (OR, 2.31; 95% CI,
0.91–5.47; P¼0.076). Similarly, AF was an independent predictor of
1-year mortality. Therefore, AF seems to be closely associated with
short- or mid-term mortality, but not with long-term mortality. In our
study, most patients were treated with ACE-I or ARB, β-blockers, and
statin. Appropriate treatment including not only early reperfusion
therapy but also the above-mentioned drugs may be decreasing the
prognostic impact of AF on long-term mortality.
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4.4. Limitation
Our study has several limitations. All analyses were based on
observational data, and the development or termination of AF
during the postdischarge periods was not included in our database.
Moreover, ECG was not continuously monitored during all periods
of hospitalization, and, therefore, it might not have captured all of
the AF episodes particularly in patients with asymptomatic tran-
sient or paroxysmal AF. We categorized patients with a history of
paroxysmal or transient AF but without recurrence of AF during
index hospitalization into the non-AF group; however, there might
be patients incorrectly categorized into the non-AF group.
4.5. Conclusions
Even in the PCI era, AF remains a common and important
complication of AMI. Patients with AF were older, were in worse
health, and had more complicated clinical events. Patients with AF
had higher in-hospital and long-term mortalities; however, the
differences were attenuated after adjustment for baseline char-
acteristics. Although the appropriate treatment, including early
reperfusion therapy, may be decreasing the prognostic impact of
AF in AMI patients, greater attention to the management of AF
complicating AMI, particularly among high-risk patients, may be
warranted.
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